dc.contributor.author
LeVine, Dana N.
dc.contributor.author
Kidd, Linda
dc.contributor.author
Garden, Oliver A.
dc.contributor.author
Brooks, Marjory B.
dc.contributor.author
Goggs, Robert
dc.contributor.author
Kohn, Barbara
dc.contributor.author
Mackin, Andrew J.
dc.contributor.author
Eldermire, Erin R. B.
dc.contributor.author
Chang, Yu-Mei
dc.contributor.author
Allen, Julie
dc.date.accessioned
2024-07-29T12:10:52Z
dc.date.available
2024-07-29T12:10:52Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/43975
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-43684
dc.description.abstract
Immune thrombocytopenia (ITP) is the most common acquired primary hemostatic disorder in dogs. Immune thrombocytopenia less commonly affects cats but is an important cause of mortality and treatment-associated morbidity in both species. Immune thrombocytopenia remains a diagnosis of exclusion for which diagnostic guidelines are lacking. Primary, or non-associative, ITP refers to autoimmune platelet destruction. Secondary, or associative, ITP arises in response to an underlying disease trigger. However, evidence for which comorbidities serve as ITP triggers has not been systematically evaluated. To identify key diagnostic steps for ITP and important comorbidities associated with secondary ITP, we developed 12 Population Evaluation/Exposure Comparison Outcome (PECO) format questions. These questions were addressed by evidence evaluators utilizing a literature pool of 287 articles identified by the panelists using a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations that then were integrated by diagnosis and comorbidity domain chairs. The revised PECO responses underwent a Delphi survey process to reach consensus on final guidelines. A combination of panel expertise and PECO responses were employed to develop algorithms for diagnosis of ITP in dogs and cats, which also underwent 4 iterations of Delphi review. Comorbidity evidence evaluators employed an integrated measure of evidence (IME) tool to determine evidence quality for each comorbidity; IME values combined with evidence summaries for each comorbidity were integrated to develop ITP screening recommendations, which also were subjected to Delphi review. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The final consensus statement provides clinical guidelines for the diagnosis of, and underlying disease screening for, ITP in dogs and cats. The systematic consensus process identified numerous knowledge gaps that should guide future studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Treatment of Immune Thrombocytopenia.
en
dc.format.extent
24 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
immune-mediated
en
dc.subject
thrombopoietin
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::630 Landwirtschaft::630 Landwirtschaft und verwandte Bereiche
dc.title
ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/jvim.16996
dcterms.bibliographicCitation.journaltitle
Journal of Veterinary Internal Medicine
dcterms.bibliographicCitation.number
4
dcterms.bibliographicCitation.pagestart
1958
dcterms.bibliographicCitation.pageend
1981
dcterms.bibliographicCitation.volume
38
dcterms.bibliographicCitation.url
https://doi.org/10.1111/jvim.16996
refubium.affiliation
Veterinärmedizin
refubium.affiliation.other
Klein- und Heimtierklinik
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1939-1676
refubium.resourceType.provider
WoS-Alert